New hope for breast cancer patients: drug combo targets residual disease

NCT ID NCT07400523

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Feb 10, 2026 · Last updated Jun 14, 2026 · Updated 17 times

Summary

This study tests whether adding ribociclib to standard hormone therapy can help prevent breast cancer from returning in people with hormone receptor-positive, HER2-negative early breast cancer who still have cancer after initial chemotherapy. About 446 participants will be randomly assigned to receive either the drug combo or hormone therapy alone. The main goal is to see if the combo improves how long people live without their cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Affiliated Hospital of Guangdong Medical University
RECRUITING

Zhanjiang, Guangdong, 524000, China

Contact Phone: •••-•••-••••
Shantou Central Hospital
RECRUITING

Shantou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sun Yat-sen Memorial Hospital
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
the First Affiliated Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BREAST CANCER